Express Mail No: EV 544892883 US

Sheet 1 of 6 of List of References

MAY 2 4 2007

LIST OF REFERENCES GEVED BY APPLICANT

(Use several sheets if necessary)

_		
	ATTY. DOCKET NO. 10589-040	APPLICATION NO. 10/519,243
-	APPLICANT	
	Welch et al.	T
	FILING DATE	ART UNIT
	March 23, 2005	1634

			U.S. P.	ATENT DOCUMENTS	
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR
/EW/	A01	4,668,625	05/26/87	Cambiaghi et al.	T.OOKES 74 T.E.W.
1	A02	5,015,570	05/14/91	Scangos et al.	
	A03	5,510,240	04/23/96	Lam et al.	
	A04	5,593,835	01/14/97	Rando et al.	
	A05	5,641,627	06/24/97	Moehle	
	A06	5,650,316	07/22/97	Aggarwal et al.	
	A07	5,663,317	09/02/97	Falkow et al.	
	A08	5,666,341	09/09/97	Horibe et al.	
	A09	5,667,975	09/16/97	Dykstra et al.	
	A10	5,679,566	10/21/97	He et al.	
	A11	5,712,096	01/27/98	Stern et al.	
	A12	5,716,825	02/10/98	Hancock et al.	
	A13	5,807,682	09/15/98	Grossman et al.	
	A14	5,840,702	11//24/98	Bedwell	
	A15	5,866,341	02/02/99	Spinella et al.	
	A16	5,871,923	02/16/99	Moehle	
	A17	6,004,749	12/21/99	Giordano et al.	
	A18	6,060,240	05/09/00	Kamb et al.	
	A19	6,071,700	06/06/00	He et al.	
	A20	6,090,912	07/18/00	Lebl et al.	
	A21	6,107,029	08/22/00	Giordano	
en 11	A22	6,147,344	11/14/00	Annis et al.	
	A23	6,207,391	03/27/01	Wu et al.	
	A24	6,211,477	04/03/01	Cardott et al.	
	A25	6,232,075	05/15/01	Williams	
	A26	6,320,040	11/20/01	Cook et al.	
	A27	6,329,146	12/11/01	Crooke et al.	
	A28	6,355,428	03/12/02	Schroth et al.	·
V	A29	6,391,542	05/12/02	Anderson et al.	

EXAMINER	
NYI-3900168v3	

/Ethan Whisenant/

DATE CONSIDERED

06/14/2007

Sheet 2 of 6 of List of References

ATTY. DOCKET NO. 10589-040-999 10/519,243

APPLICANT Welch et al.

FILING DATE March 23, 2005 1634

			U.S. P	ATENT DOCUMENTS		
*EXAMINER INITIAL	T	DOCUMENT NUMBER	DATE	· NAME	PAGES, COLUMNS, LINES, WHEI RELEVANT PASSAGES OR RELEV FIGURES APPEAR	
/EW/	A30	6,458,538	10/01/02	Beckmann et al.	FIGURES APPEAR	
1 - 441	A31	6,503,713	01/07/03	Rana		
	A32	6,503,721	01/07/03	Arenas et al.		
	A33	6,596,481	07/22/03	Rothschild et al.		
	_	7,026,122	04/11/06	Beckmann et al.		
	A34	2003/0232360	12/18/03			
	A35			Wilusz et al.		
	A36	2006/0134681	6/22/06	Beckmann et al.		
	A37	2004/0067900	4/8/04	Wilde et al.		
	A38	2006/0167065	7/27/06	Wilde et al.		
	A39	2006/0166926	7/27/06	Wilde et al.		
	A40	2006/0167623	7/27/06	Wilde et al.		
······································	A41	6,992,096	1/31/06	Karp et al.		
		FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER,			PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR	
	B01	KIND CODE (IF KNOWN) WO 99/20797 A1	04/29/99	NAME University of Massachusetts	RELEVANT FIGURES APPEAR	╁
				·	·	L
	B02	WO 01/44516 A2	06/21/01	Tularik, Inc., PTC Therapeutics, Inc.		
	B03	WO 04/010106	01/29/04	PTC Therapeutics, Inc.		
	B04	WO 97/09342	03/13/97	Scriptgen Pharmaceuticals, Inc.		

		NON	N PATENT	LITERATURE DOCUMENTS		
xamiter itials				· · · · · · · · · · · · · · · · · · ·	Etc.)	Ţη
	C01	(Include name of the author ANDREUTTI-ZAUGG,	or (in CAPITA C. ET AL., " ion of humar	AL LETTERS), Title, Date, Pertinent Pages, Inhibition of nonsense-mediated messeng MSH2 mutations with an in vivo fusion p	er RNA decay in clinical	1
	C01	(Include name of the author ANDREUTTI-ZAUGG, samples facilitates detect techniques," Cancerr Res	or (in CAPITAC., "ion of human search 1997; L., "Animog	AL LETTERS), Title, Date, Pertinent Pages, Inhibition of nonsense-mediated messenge MSH2 mutations with an in vivo fusion p 57(15): 3288-3293.	er RNA decay in clinical protein assay and conventional	1

EXAMINER /Ethan Whisenant/ DATE CONSIDERED 06/14/2007

/ 🎉		Sheet 3 of 6 of List of References	
MAY 2 4 2007	ATTY. DOCKET NO. 10589-040-999	APPLICATION NO. 10/519,243	
LIST OF REFERENCES OF BY APPLICANT	APPLICANT		
(Use several sheets if necessary)	Welch et al.		
	FILING DATE	ART UNIT	
	March 23 2005	11634	

		NON PATENT LITERATURE DOCUMENTS	
Examiner			T
Initials	├	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
/EW/	C04	BEDWELL ET AL., "Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line." Nat. Med. 1997 Nov; 3(11): 1280-1284	
	C05	BURBAUM J.J. & SIGA, N.H. ET AL., "New technologies for high-throughput screening," Curr. Opin. in Chem. Bio.; 72-78	
	C06	BUZINA, A. & SHULMAN, M.J., "Infrequent Translation of a Nonsense Codon is sufficient to decrease mRNA Level." <i>Mol. Bio. of the Cell</i> 1999 Mar; 10: 515-524	
	C07	CARTER ET AL., "A Regulatory mechanism that detects premature nonsense codons in T-cell receptor	\vdash
	07	transcripts in vivo is reversed by protein synthesis inhibitors in vitro" <i>The J. of Biol. Chem.</i> . 1996, 270(48): 28995-29003	
	C08	CARTER ET AL, "A splicing-dependent regulatory mechanism that detects translation signals." The EMBO Journal 1996; 15(21): 5965-5975	
	C09	CULBERTSON, M.R., "Unforeseen consequences for gene expression, inherited genetic disorder and cancer." TIG Nat. Med. 1999 Feb; 15(2): 74-80	
	C10	CUNDLIFFE ET AL., "How antibiotic-producing organisms avoid suicide." Ann. Rev. Microbiol. 1989; 43:207-	
	CII	CUNDLIFFE ET AL., "The Ribosome: Structure, Function, & Evolution." Schlessinger et al., eds. American Society for Microbiology, Washington D.C. 1990; pp. 479-490	
	C12	DARLING, T. N. ET AL., "Cycloheximide facilitates the identification of aberrant transcripts resulting from a novel splice-site mutation in COL17A1 in a patient with generalized atrophic benign epidermolysis bullosa." J.	
		of Invest. Derm. 1998 Febl; 110(2): 165-169	
	C13	DARLING, T.N. ET AL, "Premature Termination Codons are present on both alleles of the Bullous Pemphigoid Antigen 2/Type XVIII Collagen Gene in Five Austrian Families with Generallized Atrophic Benign Epidermolysis Bullosa. J. Invest. Derm., 1997 Apr; 108(4): 463-468	
	C14	DINMAN, J.D. ET AL., "Translating old drugs into new treatments: ribosomal frameshifting as a target for antiviral agents." Tibtech (reviews) 1998 Apr; 16:190-196	
	C15	GARVIN, A.M., "A complete protein truncation test for BRCA1 and BRCA2." Euro. J. of Human Gene 1998 May; 6(3): 226-234	
	C16	HENTZE, M.W. & KULOZIK, A.E. "A Perfect Message: RNA Surveillance and Nonsense-Mediated Decay" Cell 1999 Feb; 96: 307-310	
	C17	HOWARD ET AL., "Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations." Nat. Med. 1996 Apr; 2(4): 467-46	
	C18	HUTCHIN ET AL., "A molecular basis for human hypersensitivity to aminoglycoside antibiotics" Nucl. Acids Res 1993; 21(18):4174-4179	
	C19	JACKSON, R.J. & HUNT, T. "Preparation and Use of Nuclease-Treated Rabbit Reticulocyte Lysates for the Translation of Eukaryotic Messenger RNA." Meths. in Enzymol. 1983; 96: 50-75.	
	C20	LI, S. & WILKINSON, F., "Nonsense Surveillance in Lymphocytes?" Immunity1998 Feb; 8: 135-141	
	C21	PUROHIT ET AL., "Interactions of a small RNA with antibiotic and RNA ligands of the 30S subunit" Nature 1994; 370(6491):659-662	
	C22	RUIZ-ECHEVARRIA ET AL., "Making sense of nonsense in yeast" TIBS 1996 Nov; 21: 433-438	
V	C23	STAGE ET AL., "Inhibition of the hammerhead ribozyme by neomycin" RNA 1995; 1(1):95-101	

/Ethan Whisenant/

DATE CONSIDERED

06/14/2007

OIPE		Express Mail No: DRAFT Sheet 4 of 6 of List of References	
MAY 2 4 2007	ATTY, DOCKET NO. 10589-040-999	APPLICATION NO. 10/519,243	
LIST OF REFERENCES CIRED BY APPLICANT (USE STORING Sheets if necessary)	APPLICANT Welch et al.		
	FILING DATE March 23, 2005	ART UNIT	

		NON PATENT LITERATURE DOCUMENTS	
Examiner nitials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
/EW/	C24	VON AHSEN ET AL., "Antibiotic inhibition of group I ribozyme function." <i>Nature</i> (London) 1991; 353(6342):368-370	
	C25	WOODCOCK ET AL., "Interaction of antibiotics with A- and P-site-specific bases in 16S ribosomal RNA" EMBO J. 1991; 10:3099-3103	T
	C26	ZAPP ET AL. "Small molecules that selectively block RNA binding of HIV-I Rev protein inhibit Rev function and viral production" Cell 1993; 74(6):969-978	T
	C27	ABOUL-ELA et al., "The structure of the human immunodeficiency virus type-1 TAR RNA reveals principles of RNA recognition by Tat protein." J. Mol. Biol. 1995; 253:313-332.	
	C28	AGGARWAL et al., "Triple helix-forming oligodeoxyribonucleotides targeted to the human tumor necrosis factor, TNF, gene inhibit TNF production and block the TNF-dependent growth of human glioblastoma tumor cells." Cancer Res. 1996; 56:5156-5164	
	C29	BAKHEET et al., "ARED: human AU-rich element-containing mRNA database reveals an unexpectedly diverse functional repertoire of encoded proteins." Nucleic Acids Res. 2001; 29:246-254	
	C30	BAYER, "Towards The Chemical Synthesis of Proteins." Angew. Chem. 1991; 30:113-129.	T
	C31	BEAL & DERVAN, "Second structural motif for recognition of DNA by oligonucleotide-directed triple-helix formation." Science 1991; 251(4999):1360-1363	T
	C32	BLACKWELL ET AL., "A one-bead, one-stock solution approach to chemical genetics: part 1." Chem & Bio. 2001; 8:1167-1182.	T
	C33	CHASTAIN & TINOCO, "Structural elements in RNA." Prog. Nucleic Acid Res. Mol. Bio. 1991; 41:131-177.	T
	C34	CHOW & BOGDAN, "A structural basis for RNA-ligand interactions." Chem. Rev. 1997; 97:1489-1514.	t
	C35	CHURCHER et al., "High affinity binding of TAR RNA by the human immunodeficiency virus type-1 tat protein requires base-pairs in the RNA stem and amino acid residues flanking the basic region" J. Mol. Biol. 1993; 230:90-110.	
	C36	CLEMONS ET AL., "A one-bead, one-stock solution approach to chemical genetics: part 2." Chem & Bio. 2001; 8:1183-1195	T
	C37	CONTRERAS et al. "Simple, efficient in vitro synthesis of capped RNA useful for direct expression of cloned eukaryotic genes." Nucl. Acids. Res., 1982, 10:6353	T
	C38	CORDINGLEY et al., "Sequence-Specific Interaction of Tat Protein and Tat Peptides with the Transactivation-Responsive Sequence Element of Human Immunodeficiency Virus Type 1 in vitro." Proc. Natl. Acad. Sci. USA 1990; 87:8985-8989.	
	C39	DIGNAM et al., "Preparation of extracts from higher eukaryotes." Methods Enzymol., 1990, 182: 194-203	Γ
	C40	FELBER & PAVLAKIS, "A quantitative bioassay for HIV-1 based on trans-activation." Science 1988; 239:184-187.	
	C41	FERNANDES, "Technological advances in high-throughput screening." Curr Opin Chem Biol. 1998; 2:597-603	T
	C42	FRANKEL A. D. & PABO, "Cellular uptake of the tat protein from human immunodeficiency virus." Cell 1998; 55:1189-1194.	
	C43	GOTTESFELD et al. "Regulation of gene expression by small molecules. Nature 1997; 387(6629):202-205.	Γ
	C44	GOTTESFELD et al., "Chemical Approaches to Control Gene Expression." Gene Expr 2000; 9:77-91	T
	C45	HAMY et al., "An inhibitor of the Tat/TAR RNA interaction that effectively suppresses HIV-1 replication." Proc. Natl. Acad. Sci. USA, 1997, 94:3548-3553.	T
V	C46	HAMY et al., "A new class of HIV-1 Tat antagonist acting through Tat-TAR inhibition." Biochem 1998; 37(15):5086-5095.	Γ

/Ethan Whisenant/	DATE CONSIDERED 06/14/	2007
-------------------	------------------------	------

MAY 2-4 2007

LIST OF REFERENCES CITED BY ACTION (Use several sheets if necessary)

ATTY, DOCKET NO.	APPLICATION NO.
10589-040-999	10/519,243
APPLICANT	
Welch et al.	
FILING DATE	ART UNIT
March 23, 2005	1634

,		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	<u> </u>	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т
/EW/	C47	HARNDEN et al., "Thiazolinone Analogues of Indomycin with antiviral and antibacterial activity." J. of Med. Chem. 1978; 21:82-87	1
	C48	HELENE et al., "Control of gene expression by triple helix-forming oligonucleotides. The antigene strategy." Ann NY Acad Sci 1992; 660:27-36.	
	C49	HO et al., "Specific inhibition of formation of transcription complexes by a calicheamicin oligosaccharide: a paradigm for the development of transcriptional antagonists." Proc Natl Acad Sci USA 1994; 91(20):9203	
	C50	HUQ et al., "Controlling human immunodeficiency virus type 1 gene expression by unnatural peptides." Biochem. 1999; 38:5172	
	C51	HWANG et al., "Inhibition of gene expression in human cells through small molecule-RNA interactions." <i>Proc. Natl. Acad. Sci. USA</i> 1999; 96(23):12977-13002.	
	C52	JAKOBOVITS et al., "A discrete element 3' of human immunodeficiency virus 1 (HIV-1) and HIV-2 mRNA initiation sites mediates transcriptional activation by an HIV trans activator." Mol. Cell. Bio. 1988; 8:2555-2561.	
	C53	JHAVERI et al., "In Vitro Selection of RNA Aptamers to a Protein Target by Filter Immobilization" Curr. Prot. in Molec. Bio. 2000; 24.3.1-24.3.25	
	C54	JONES & PETERLIN, "Control of RNA initiation and elongation at the HIV-1 promoter." Annu Rev Biochem 1994; 63:717-743.	
	C55	KRIEG & MELTON, "Formation of the 3' end of histone mRNA by post-transcriptional processing." Nature, 1984, 308:203	
	C56	KURUVILLA ET AL., "Dissecting glucose signalling with diversity-oriented synthesis and small-molecule microarrays." Nature 2002; 416:653-657	16
	C57	LIU et al., "Sequence-selective carbohydrate-DNA interaction: Dimeric and monomeric forms of the calicheamicin oligosaccharide interfere with transcription factor function." <i>Proc Natl Acad Sci USA</i> 1996; 93(2):940-944.	
	C58	MAHER et al., "Oligonucleotide-directed DNA triple-helix formation: an approach to artificial repressors?" Antisense Res Dev 1991; 1(3):277-281.	
	C59	MAZUMDER et al., "Inhibition of the Human Immunodeficiency Virus Type 1 Integrase by Guanosine Quartet Structures." <i>Biochem.</i> 1996; 35:13762-13771	
	C60	MEI et al., "Discovery of selective, small-molecule inhibitors of RNA complexesI. The Tat protein/TAR RNA complexes required for HIV-1 transcription." Bioorg. Med. Chem. 1997; 5:1173-1184.	
	C61	MEI et al., "Inhibitors of protein-RNA complexation that target the RNA: specific recognition of human immunodeficiency virus type 1 TAR RNA by small organic molecules." <i>Biochem.</i> 1998; 37(40):14204-14212.	
	C62	MILLER, "Development of antisense and antigene oligonucleotide analogs." <i>Prog. Nucleic Acid Res. Mol. Bio.</i> 1996; 52:261-291.	
	C63	MILLIGAN et al., "Oligoribonucleotide synthesis using T7 RNA polymerase and synthetic DNA templates." Nucleic Acids Res. 1987;15:8783-8798.	
	C64	MISIURA et al., "Biotinyl and phosphotyrosinyl phosphoramidite derivatives useful in the incorporation of multiple reporter groups on synthetic oligonucleotides." <i>Nucleic Acids Res.</i> 1990; 18:4345-4354.	
	C65	MULLER et al., "Interaction of fluorescently labeled dideoxyncleotides with HIV-1 reverse transcriptase." Biochem. 1991; 30:3709-3715.	
	C66	NEEDELS et al., "Generation and screening of an oligonucleotide-encoded synthetic peptide library", <i>Proc. Natl. Acad. Sci. USA</i> 1993; 90:10700-10704.	
	C67	NEENHOLD & RANA, "Major groove opening at the HIV-1 Tat binding site of TAR RNA evidenced by a rhodium probe." <i>Biochem.</i> 1995; 34:6303-6309.	
V	C68	NIELSEN, "Applications of peptide nucleic acids." Curr. Opin. Biotechnol. 1999; 10(1):71-75.	

1	E.	X.	١.	M	II	N	L	R

/Ethan Whisenant/

DATE CONSIDERED

06/14/2007

OIPE	ATTY. DOCKET NO. 10589-040-999	APPLICATION NO. 10/519,243
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)) MAY 24 7007	APPLICANT Welch et al.	
FARADER TRADER	FILING DATE March 23, 2005	art unit 1634

		NON PATENT LITERATURE DOCUMENTS	
Examiner nitials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	т
/EW/	C69	NORDEEN, "Luciferase reporter gene vectors for analysis of promoters and enhancers." <i>Bio Techniques</i> 1998; 6:454-457.	
	C70	OHLMEYER et al., "Complex synthetic chemical libraries indexed with molecular tags." <i>Proc. Natl. Acad. Sci. USA</i> 1993; 90(23):10922-10926	
	C71	OJWANG et al., "Achieving antisense inhibition by oligodeoxynucleotides containing N7 modified 2'-deoxyguanosine using tumor necrosis factor receptor type 1." METHODS: A Companion to Methods in Enzymology 1999; 18:244-251	
	C72	PING et al., "Dynamics of RNA-protein interactions in the HIV-1 Rev-RRE complex visualized by 6-thioguanosine-mediated photocrosslinking" RNA 1997; 3:850-860.	1
	C73	PUGLISI et al., "Conformation of the TAR RNA-arginine complex by NMR spectroscopy." Science 1992; 257:76-80.	
	C74	RANDO et al., "Biologic activity of guanosine quartet forming oligonucleotides" in "Applied Antisense Oligonucleotide Technology" Stein and Krieg, eds, John Wiley and Sons, New York, 1998; pages 335-352	
	C75	SCARINGE et al., "Chemical synthesis of biologically active oligoribonucleotides using beta-cyanoethyl protected ribonucleoside phosphoramidites. <i>Nucleic Acids Res</i> 1990; 18:5433-5441.	
	C76	SHAH et al., "Synthesis of uridine phosphoramidite analogs: reagents for site-specific incorporation of photoreactive sites into RNA sequences." <i>Bioconjugate Chem.</i> 1994; 5:508-512.	
	C77	SHAH et al., "Incorporation of an artificial protease and nuclease at the HIV-1 Tat binding site of transactivation responsive RNA." Bioconjugate Chem. 1996; 7:283-289.	
	C78	STERNSON ET AL., "Split-Pool Synthesis of 1,3-Dioxanes Leading to Arrayed Stock Solutions of Single Compounds Sufficient for Multiple Phenotypic and Protein-Binding Assays." J. Am. Chem. Soc. 2001; 123:1740-1747	
	C79	STILL, "Discovery of sequence-selective peptide binding by synthetic receptors using encoded combinatorial libraries." Accounts of Chem. Res. 1996; 29:(3) 155-163.	
	C80	WANG & RANA, "RNA conformation in the Tat-TAR complex determined by site-specific photo-cross-linking." <i>Biochem</i> 1996; 35:6491-6499.	
	C81	WEEKS & CROTHERS, "Major groove accessibility of RNA." Science 1993; 261(5128):1574-1577.	
	C82	WHITE et al., "Recognition of the four Watson-Crick base pairs in the DNA minor groove by synthetic ligands." Nature 1998; 391(6666):468-471.	T
	C83	XAVIER et al., "RNA as a drug target: methods for biophysical characterization and screening." Trends Biotechnol 2001; 18:349-356	T
$\overline{\mathbb{V}}$	C84	XIAN et al., "DNA-protein binding assays from single sea urchin egg: a high sensitivity capillary electrophoresis method." <i>Proc. Natl. Acad Sci.</i> 1996; 93:86-90	

EXAMINER /Ethan Whisenant/	DATE CONSIDERED	06/14/2007	
----------------------------	-----------------	------------	--

Express Mail No: EV 544892883 US

Sheet 1 of 6 of List of References

ATTY. DOCKET NO. APPLICATION NO. 10589-040 10/519,243 LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) **APPLICANT** Welch et al. MAY 2 4 2007 FILING DATE ART UNIT March 23, 2005 1634

CANDENIAN .						
U.S. PATENT DOCUMENTS						
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVAN	
/EW/	A01	4,668,625	05/26/87	Cambiaghi et al.	FIGURES APPEAR	
	A02	5,015,570	05/14/91	Scangos et al.		
	A03	5,510,240	04/23/96	Lam et al.		
	A04	5,593,835	01/14/97	Rando et al.		
	A05	5,641,627	06/24/97	Moehle		
	A06	5,650,316	07/22/97	Aggarwal et al.		
	A07	5,663,317	09/02/97	Falkow et al.		
	A08	5,666,341	09/09/97	Horibe et al.		
	A09	5,667,975	09/16/97	Dykstra et al.		
	A10	5,679,566	10/21/97	He et al.		
	All	5,712,096	01/27/98	Stern et al.		
	A12	5,716,825	02/10/98	Hancock et al.		
	A13	5,807,682	09/15/98	Grossman et al.		
	A14	5,840,702	11//24/98	Bedwell		
	A15	5,866,341	02/02/99	Spinella et al.		
	A16	5,871,923	02/16/99	Moehle		
	A17	6,004,749	12/21/99	Giordano et al.		
	A18	6,060,240	05/09/00	Kamb et al.		
	A19	6,071,700	06/06/00	He et al.		
	A20	6,090,912	07/18/00	Lebi et al.		
	A21	6,107,029	08/22/00	Giordano		
	A22	6,147,344	11/14/00	Annis et al.		
	A23	6,207,391	03/27/01	Wu et al.		
	A24	6,211,477	04/03/01	Cardott et al.		
	A25	6,232,075	05/15/01	Williams		
	A26	6,320,040	11/20/01	Cook et al.		
	A27	6,329,146	12/11/01	Crooke et al.		
	A28	6,355,428	03/12/02	Schroth et al.		
¥	A29	6,391,542	05/12/02	Anderson et al.		

EXAMINER	
NY1-3900168v	3

/Ethan Whisenant/

DATE CONSIDERED

06/14/2007

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. APPLICATION NO. 10589-040-999 10/519,243 APPLICANT			
MAY 2 4 2007	Welch et al. FILING DATE March 23, 2005	ART UNIT 1634		

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVAN FIGURES APPEAR
/EW/	A30	6,458,538	10/01/02	Beckmann et al.	HOURES AFFEAR
	A31	6,503,713	01/07/03	Rana	
	A32	6,503,721	01/07/03	Arenas et al.	
	A33	6,596,481	07/22/03	Rothschild et al.	
	A34	7,026,122	04/11/06	Beckmann et al.	
	A35	2003/0232360	12/18/03	Wilusz et al.	
	A36	2006/0134681	6/22/06	Beckmann et al.	
	A37	2004/0067900	4/8/04	Wilde et al.	
	A38	2006/0167065	7/27/06	Wilde et al.	
	A39	2006/0166926	7/27/06	Wilde et al.	
	A40	2006/0167623	7/27/06	Wilde et al.	
	A41	6,992,096	1/31/06	Karp et al.	

FOREIGN PATENT DOCUMENTS						
	FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN)	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR		
B01	WO 99/20797 A1	04/29/99	University of Massachusetts	RELEVANT FIGURES APPEAR		
B02	WO 01/44516 A2	06/21/01	Tularik, Inc., PTC Therapeutics, Inc.			
B03	WO 04/010106	01/29/04	PTC Therapeutics, Inc.		-	
B04	WO 97/09342	03/13/97	Scriptgen Pharmaceuticals, Inc.		 	

	NON PATENT LITERATURE DOCUMENTS						
Examine Initials	er	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т				
	C01	ANDREUTTI-ZAUGG, C. ET AL., "Inhibition of nonsense-mediated messenger RNA decay in clinical samples facilitates detection of human MSH2 mutations with an in vivo fusion protein assay and conventional techniques," Cancerr Research 1997; 57(15): 3288-3293.					
	C02	BARTON-DAVIS ET AL., "Animoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice" J. of Clin. Invesy. 1999 Aug; 104(4): 375-381					
\bigvee	C03	BATEMAN J.F. ET AL., "Reliable and sensitive detection of premature termination mutations using a protein truncation test designed to overcome problems of nonsense-mediated mRNA instability." <i>Human Mutation</i> 1999; 13(4): 311-317					

	EXAMINER	/Ethan Whisenant/	DATE CONSIDERED	06/14/2007	
-[

[•]EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

NYI-3900168v3

	ATTY. DOCKET NO.	ATTY. DOCKET NO. APPLICATION NO. 10589-040-999 10/519,243				
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Welch et al.					
MAY 2 4 2007	FILING DATE March 23, 2005	ART UNIT 1634				

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
/EW/	C04	BEDWELL ET AL., "Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line." Nat. Med. 1997 Nov; 3(11): 1280-1284	<u> </u>
	C05	BURBAUM J.J. & SIGA, N.H. ET AL., "New technologies for high-throughput screening," Curr. Opin. in Chem. Bio.; 72-78	
	C06	BUZINA, A. & SHULMAN, M.J., "Infrequent Translation of a Nonsense Codon is sufficient to decrease mRNA Level." Mol. Bio. of the Cell 1999 Mar; 10: 515-524	
	C07	CARTER ET AL., "A Regulatory mechanism that detects premature nonsense codons in T-cell receptor transcripts in vivo is reversed by protein synthesis inhibitors in vitro" <i>The J. of Biol. Chem.</i> . 1996, 270(48): 28995-29003	
·	C08	CARTER ET AL, "A splicing-dependent regulatory mechanism that detects translation signals." The EMBO Journal 1996; 15(21): 5965-5975	
	C09	CULBERTSON, M.R., "Unforeseen consequences for gene expression, inherited genetic disorder and cancer." TIG Nat. Med. 1999 Feb; 15(2): 74-80	
	C10	CUNDLIFFE ET AL., "How antibiotic-producing organisms avoid suicide. " Ann. Rev. Microbiol. 1989; 43:207-233	
	CII	CUNDLIFFE ET AL., "The Ribosome: Structure, Function, & Evolution." Schlessinger et al., eds. American Society for Microbiology, Washington D.C. 1990; pp. 479-490	
	C12	DARLING, T. N. ET AL., "Cycloheximide facilitates the identification of aberrant transcripts resulting from a novel splice-site mutation in COL17A1 in a patient with generalized atrophic benign epidermolysis bullosa." J. of Invest. Derm. 1998 Febl; 110(2): 165-169	
	C13	DARLING, T.N. ET AL, "Premature Termination Codons are present on both alleles of the Bullous Pemphigoid Antigen 2/Type XVIII Collagen Gene in Five Austrian Families with Generallized Atrophic Benign Epidermolysis Bullosa. J. Invest. Derm. 1997 Apr; 108(4): 463-468	
	C14	DINMAN, J.D. ET AL., "Translating old drugs into new treatments: ribosomal frameshifting as a target for antiviral agents." Tibtech (reviews) 1998 Apr; 16:190-196	
	C15	GARVIN, A.M., "A complete protein truncation test for BRCA1 and BRCA2." Euro. J. of Human Gene 1998 May; 6(3): 226-234	
	C16	HENTZE, M.W. & KULOZIK, A.E. "A Perfect Message: RNA Surveillance and Nonsense-Mediated Decay" Cell 1999 Feb; 96: 307-310	
	C17-	HOWARD ET AL., "Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations." Nat. Med. 1996 Apr; 2(4): 467-46	
	C18	HUTCHIN ET AL., "A molecular basis for human hypersensitivity to aminoglycoside antibiotics" Nucl. Acids Res 1993; 21(18):4174-4179	
	C19	JACKSON, R.J. & HUNT, T. "Preparation and Use of Nuclease-Treated Rabbit Reticulocyte Lysates for the Translation of Eukaryotic Messenger RNA." Meths. in Enzymol. 1983; 96: 50-75.	
	C20	LI, S. & WILKINSON, F., "Nonsense Surveillance in Lymphocytes?" Immunity 1998 Feb; 8: 135-141	
	C21	PUROHIT ET AL., "Interactions of a small RNA with antibiotic and RNA ligands of the 30S subunit" Nature 1994; 370(6491):659-662	
	C22	RUIZ-ECHEVARRIA ET AL., "Making sense of nonsense in yeast" TIBS 1996 Nov; 21: 433-438	
$\overline{\mathbf{V}}$	C23	STAGE ET AL., "Inhibition of the hammerhead ribozyme by neomycin" RNA 1995; 1(1):95-101	

EXAMINER	/Ethan Whisenant/	DATE CONSIDERED	06/14/2007

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

NYI-3900168v3

	ATTY. DOCKET NO. 10589-040-999	APPLICATION NO. 10/519,243
LIST OF REFERENCES CITED BY APPLICANT (Upa several sheets if necessary)	APPLICANT Welch et al.	
MAY 2 4 2007 By	FILING DATE March 23, 2005	ART UNIT 1634

		A		
	*	Pra n	NON PATENT LITERATURE DOCUMENTS	
Exam Initial			(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т
	EW/	C24	VON AHSEN ET AL., "Antibiotic inhibition of group I ribozyme function." Nature (London) 1991;	† `
	_ / / /	-	353(6342):368-370	↓
		C25	WOODCOCK ET AL., "Interaction of antibiotics with A- and P-site-specific bases in 16S ribosomal RNA" EMBO J. 1991; 10:3099-3103	1
		C26	ZAPP ET AL. "Small molecules that selectively block RNA binding of HIV-1 Rev protein inhibit Rev function and	
	<u> </u>		viral production" Cell 1993; 74(6):969-978	
		C27	ABOUL-ELA et al., "The structure of the human immunodeficiency virus type-1 TAR RNA reveals principles	
	 	C28	of RNA recognition by Tat protein." J. Mol. Biol. 1995; 253:313-332. AGGARWAL et al., "Triple helix-forming oligodeoxyribonucleotides targeted to the human tumor necrosis	├
		C28	factor, TNF, gene inhibit TNF production and block the TNF-dependent growth of human glioblastoma tumor cells." Cancer Res. 1996; 56:5156-5164	
		C29	BAKHEET et al., "ARED: human AU-rich element-containing mRNA database reveals an unexpectedly diverse functional repertoire of encoded proteins." Nucleic Acids Res. 2001; 29:246-254	
		C30	BAYER, "Towards The Chemical Synthesis of Proteins." Angew. Chem. 1991; 30:113-129.	
		C31	BEAL & DERVAN, "Second structural motif for recognition of DNA by oligonucleotide-directed triple-helix formation." Science 1991; 251(4999):1360-1363	
		C32	BLACKWELL ET AL., "A one-bead, one-stock solution approach to chemical genetics: part 1." Chem & Blo. 2001; 8:1167-1182.	
		C33	CHASTAIN & TINOCO, "Structural elements in RNA." Prog. Nucleic Acid Res. Mol. Bio. 1991; 41:131-177.	
		C34	CHOW & BOGDAN, "A structural basis for RNA-ligand interactions." Chem. Rev. 1997; 97:1489-1514.	
		C35	CHURCHER et al., "High affinity binding of TAR RNA by the human immunodeficiency virus type-1 tat protein requires base-pairs in the RNA stem and amino acid residues flanking the basic region" J. Mol. Biol. 1993; 230:90-110.	
		C36	CLEMONS ET AL., "A one-bead, one-stock solution approach to chemical genetics: part 2." Chem & Bio. 2001; 8:1183-1195	
		C37	CONTRERAS et al. "Simple, efficient in vitro synthesis of capped RNA useful for direct expression of cloned eukaryotic genes." Nucl. Acids. Res., 1982, 10:6353	
		C38	CORDINGLEY et al., "Sequence-Specific Interaction of Tat Protein and Tat Peptides with the Transactivation-Responsive Sequence Element of Human Immunodeficiency Virus Type 1 in vitro." <i>Proc. Natl. Acad. Sci. USA</i> 1990; 87:8985-8989.	
		C39	DIGNAM et al., "Preparation of extracts from higher eukaryotes." Methods Enzymol., 1990, 182: 194-203	
		C40	FELBER & PAVLAKIS, "A quantitative bioassay for HIV-1 based on trans-activation." Science 1988; 239:184-187.	
		C41	FERNANDES, "Technological advances in high-throughput screening." Curr Opin Chem Biol. 1998; 2:597-603	
		C42	FRANKEL A. D. & PABO, "Cellular uptake of the tat protein from human immunodeficiency virus." Cell 1998; 55:1189-1194.	
		C43	GOTTESFELD et al. "Regulation of gene expression by small molecules. Nature 1997; 387(6629):202-205.	
		C44	GOTTESFELD et al., "Chemical Approaches to Control Gene Expression." Gene Expr 2000; 9:77-91	.
		C45	HAMY et al., "An inhibitor of the Tat/TAR RNA interaction that effectively suppresses HIV-1 replication." Proc. Natl. Acad. Sci. USA, 1997, 94:3548-3553.	
	/	C46	HAMY et al., "A new class of HIV-1 Tat antagonist acting through Tat-TAR inhibition." Biochem 1998; 37(15):5086-5095.	

EXAMINER	/Ethan Whisenant/	DATE CONSIDERED	06/14/2007
ACVANDICE. I			

[•]EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ATTY. DOCKET NO. 10589-040-999	APPLICATION NO. 10/519,243
APPLICANT Welch et al.	
FILING DATE March 23, 2005	ART UNIT 1634
	10589-040-999 APPLICANT Welch et al. FILING DATE

· ·	HOEMAR	NON PATENT LITERATURE DOCUMENTS	
Examiner	T		Т
Initials /EW/	C47	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.) HARNDEN et al., "Thiazolinone Analogues of Indomycin with antiviral and antibacterial activity." J. of Med. Chem. 1978; 21:82-87	
	C48	HELENE et al., "Control of gene expression by triple helix-forming oligonucleotides. The antigene strategy." Ann N Y Acad Sci 1992; 660:27-36.	
	C49	HO et al., "Specific inhibition of formation of transcription complexes by a calicheamicin oligosaccharide: a paradigm for the development of transcriptional antagonists." Proc Natl Acad Sci USA 1994; 91(20):9203	
	C50	HUQ et al., "Controlling human immunodeficiency virus type 1 gene expression by unnatural peptides." Biochem. 1999; 38:5172	
	C51	HWANG et al., "Inhibition of gene expression in human cells through small molecule-RNA interactions." Proc. Natl. Acad. Sci. USA 1999; 96(23):12977-13002.	
	C52	JAKOBOVITS et al., "A discrete element 3' of human immunodeficiency virus 1 (HIV-1) and HIV-2 mRNA initiation sites mediates transcriptional activation by an HIV trans activator." Mol. Cell. Bio. 1988; 8:2555-2561.	
	C53	JHAVERI et al., "In Vitro Selection of RNA Aptamers to a Protein Target by Filter Immobilization" Curr. Prot. in Molec. Bio. 2000; 24.3.1-24.3.25	
	C54	JONES & PETERLIN, "Control of RNA initiation and elongation at the HIV-1 promoter." Annu Rev Biochem 1994; 63:717-743.	
	C55	KRIEG & MELTON, "Formation of the 3' end of histone mRNA by post-transcriptional processing." Nature, 1984, 308:203	
	C56	KURUVILLA ET AL., "Dissecting glucose signalling with diversity-oriented synthesis and small-molecule microarrays." Nature 2002; 416:653-657	
	C57	LIU et al., "Sequence-selective carbohydrate-DNA interaction: Dimeric and monomeric forms of the calicheamicin oligosaccharide interfere with transcription factor function." <i>Proc Natl Acad Sci USA</i> 1996; 93(2):940-944.	
	C58	MAHER et al., "Oligonucleotide-directed DNA triple-helix formation: an approach to artificial repressors?" Antisense Res Dev 1991; 1(3):277-281.	
	C59	MAZUMDER et al., "Inhibition of the Human Immunodeficiency Virus Type 1 Integrase by Guanosine Quartet Structures." Biochem. 1996; 35:13762-13771	
	C60	MEI et al., "Discovery of selective, small-molecule inhibitors of RNA complexesI. The Tat protein/TAR RNA complexes required for HIV-1 transcription." Bioorg. Med. Chem. 1997; 5:1173-1184.	
	C61	MEI et al., "Inhibitors of protein-RNA complexation that target the RNA: specific recognition of human immunodeficiency virus type 1 TAR RNA by small organic molecules." <i>Biochem.</i> 1998; 37(40):14204-14212.	
	C62	MILLER, "Development of antisense and antigene oligonucleotide analogs." Prog. Nucleic Acid Res. Mol. Bio. 1996; 52:261-291.	,
	C63	MILLIGAN et al., "Oligoribonucleotide synthesis using T7 RNA polymerase and synthetic DNA templates." Nucleic Acids Res. 1987;15:8783-8798.	
	C64	MISIURA et al., "Biotinyl and phosphotyrosinyl phosphoramidite derivatives useful in the incorporation of multiple reporter groups on synthetic oligonucleotides." Nucleic Acids Res. 1990; 18:4345-4354.	
	C65	MULLER et al., "Interaction of fluorescently labeled dideoxyncleotides with HIV-1 reverse transcriptase." Biochem. 1991; 30:3709-3715.	
	C66	NEEDELS et al., "Generation and screening of an oligonucleotide-encoded synthetic peptide library", Proc. Natl. Acad. Sci. USA 1993; 90:10700-10704.	
	C67	NEENHOLD & RANA, "Major groove opening at the HIV-1 Tat binding site of TAR RNA evidenced by a rhodium probe." <i>Biochem.</i> 1995; 34:6303-6309.	
$ \Psi$	C68	NIELSEN, "Applications of peptide nucleic acids." Curr. Opin. Biotechnol. 1999; 10(1):71-75.	

EXAMINER	/Ethan Whisenant/	1	DATE CONSIDERED	06/14/2007

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. NYI-3900168v3

	ATTY. DOCKET NO. 10589-040-999	APPLICATION NO. 10/519,243	
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Welch et al.		
i and	FILING DATE March 23, 2005	ART UNIT	
MAY 2 TOO.	Widicii 25, 2005	1034	

138	STOTAL TR	NON PATENT LITERATURE DOCUMENTS	
xaminer iitials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T,
/EW/	C69	NORDEEN, "Luciferase reporter gene vectors for analysis of promoters and enhancers." Bio Techniques 1998; 6:454-457.	Ť
	C70	OHLMEYER et al., "Complex synthetic chemical libraries indexed with molecular tags." Proc. Natl. Acad. Sci. USA 1993; 90(23):10922-10926	T
	C71	OJWANG et al., "Achieving antisense inhibition by oligodeoxynucleotides containing N7 modified 2'-deoxyguanosine using tumor necrosis factor receptor type 1." METHODS: A Companion to Methods in Enzymology 1999; 18:244-251	
	C72	PING et al., "Dynamics of RNA-protein interactions in the HIV-1 Rev-RRE complex visualized by 6-thioguanosine-mediated photocrosslinking" RNA 1997; 3:850-860.	Ť
	C73	PUGLISI et al., "Conformation of the TAR RNA-arginine complex by NMR spectroscopy." Science 1992; 257:76-80.	Ť
	C74	RANDO et al., "Biologic activity of guanosine quartet forming oligonucleotides" in "Applied Antisense Oligonucleotide Technology" Stein and Krieg, eds, John Wiley and Sons, New York, 1998; pages 335-352	T
	C75	SCARINGE et al., "Chemical synthesis of biologically active oligoribonucleotides using beta-cyanoethyl protected ribonucleoside phosphoramidites. Nucleic Acids Res 1990; 18:5433-5441.	T
	C76	SHAH et al., "Synthesis of uridine phosphoramidite analogs: reagents for site-specific incorporation of photoreactive sites into RNA sequences." Bioconjugate Chem. 1994; 5:508-512.	T
	C77	SHAH et al., "Incorporation of an artificial protease and nuclease at the HIV-1 Tat binding site of transactivation responsive RNA." Bioconjugate Chem. 1996; 7:283-289.	T
	C78	STERNSON ET AL., "Split-Pool Synthesis of 1,3-Dioxanes Leading to Arrayed Stock Solutions of Single Compounds Sufficient for Multiple Phenotypic and Protein-Binding Assays." J. Am. Chem. Soc. 2001; 123:1740-1747	
	C79	STILL, "Discovery of sequence-selective peptide binding by synthetic receptors using encoded combinatorial libraries." Accounts of Chem. Res. 1996; 29:(3) 155-163.	Ī
	C80	WANG & RANA, "RNA conformation in the Tat-TAR complex determined by site-specific photo-cross-linking." Biochem 1996; 35:6491-6499.	T
	C81	WEEKS & CROTHERS, "Major groove accessibility of RNA." Science 1993; 261(5128):1574-1577.	T
	C82	WHITE et al., "Recognition of the four Watson-Crick base pairs in the DNA minor groove by synthetic ligands." Nature 1998; 391(6666):468-471.	T
	C83	XAVIER et al., "RNA as a drug target: methods for biophysical characterization and screening." Trends Biotechnol 2001; 18:349-356	T
V	C84	XIAN et al., "DNA-protein binding assays from single sea urchin egg: a high sensitivity capillary electrophoresis method." <i>Proc. Natl. Acad Sci.</i> 1996; 93:86-90	T

EXAMINER	/Ethan Whisenant/	DATE CONSIDERED	№ 06/14/2007
----------	-------------------	-----------------	---------------------